Novo Nordisk CEO Discusses Sales Guidance, Wegovy Launch, and Competition

2026 Sales Guidance and Headwinds

• 📉 Novo Nordisk forecasts a 5% to 13% decline in sales at constant exchange rates for 2026, a wider range than analysts anticipated.
• ⚠️ This guidance reflects anticipated headwinds from drug pricing pressures and increasing competition in the weight-loss drug market.

Strong Uptake of Oral Wegovy

• 🚀 The launch of Novo Nordisk's oral GLP-1 treatment, Wegovy, has seen significant patient adoption, with over 170,000 patients starting the pill within its first four weeks.
• 💡 The oral Wegovy is highlighted as the most efficacious GLP-1 pill available, offering 17% weight loss and being welcomed by patients for its affordability and effectiveness.

Competition and Market Dynamics

• ⚔️ Novo Nordisk faces mounting competition from companies like Eli Lilly & Co. and telehealth providers selling lower-cost versions of weight-loss drugs.
• ⚖️ The company aims to maintain its market position by emphasizing the magnitude of weight loss achieved with its products, noting its pill offers 16.6% weight loss compared to a competitor's 12%.

Financial Discipline and Future Investments

• 💰 Novo Nordisk has implemented financial discipline, including past headcount reductions, to navigate anticipated sales declines.
• 🌱 Despite current financial headwinds, the company sees positive growth in other business areas, including increased product production, patient acquisition, and pipeline acceleration, allowing for continued investment.

Strategic Focus and Profitability

• 🎯 Novo Nordisk is primarily focusing on the diabetes and obesity markets, which affect two billion people globally with significant unmet needs.
• 📈 The company believes these markets remain profitable, even at lower price points, due to large volumes and a segmented approach to pricing across different products and portfolios.